MX370970B - Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. - Google Patents

Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica.

Info

Publication number
MX370970B
MX370970B MX2019001915A MX2019001915A MX370970B MX 370970 B MX370970 B MX 370970B MX 2019001915 A MX2019001915 A MX 2019001915A MX 2019001915 A MX2019001915 A MX 2019001915A MX 370970 B MX370970 B MX 370970B
Authority
MX
Mexico
Prior art keywords
treatment
compound
orthostatic hypotension
neurogenic orthostatic
neurogenic
Prior art date
Application number
MX2019001915A
Other languages
English (en)
Other versions
MX2019001915A (es
Inventor
S Hegde Sharathchandra
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019001915A publication Critical patent/MX2019001915A/es
Publication of MX370970B publication Critical patent/MX370970B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere al uso del compuesto 4-[2-(2,4,6-trifluoro fenoximetil)-fenil]piperidina, o una sal farmacéuticamente aceptable del mismo, para el tratamiento de hipotensión ortostática neurogénica y sus síntomas.
MX2019001915A 2016-08-30 2017-08-24 Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. MX370970B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381114P 2016-08-30 2016-08-30
PCT/US2017/048324 WO2018044667A1 (en) 2016-08-30 2017-08-24 Compound for use in the treatment of neurogenic orthostatic hypotension

Publications (2)

Publication Number Publication Date
MX2019001915A MX2019001915A (es) 2019-07-15
MX370970B true MX370970B (es) 2020-01-10

Family

ID=59772789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001915A MX370970B (es) 2016-08-30 2017-08-24 Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica.

Country Status (20)

Country Link
US (1) US10238642B2 (es)
EP (1) EP3506900A1 (es)
JP (4) JP6853345B2 (es)
KR (1) KR102054208B1 (es)
CN (3) CN115813923A (es)
AU (1) AU2017321016B2 (es)
BR (1) BR112019003201A2 (es)
CA (1) CA3032168C (es)
CL (1) CL2019000377A1 (es)
CO (1) CO2019001137A2 (es)
IL (1) IL288194B2 (es)
MX (1) MX370970B (es)
MY (1) MY194181A (es)
NZ (1) NZ750392A (es)
PH (1) PH12019500252A1 (es)
RU (1) RU2723095C1 (es)
SG (1) SG11201901477PA (es)
TW (1) TWI731153B (es)
WO (1) WO2018044667A1 (es)
ZA (1) ZA201900640B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2358674E (pt) 2008-11-14 2013-03-05 Theravance Inc Processo de preparação de compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
US10640467B2 (en) 2018-06-01 2020-05-05 Theravance Biopharma R&D Ip, Llc Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid
US20220168301A1 (en) * 2019-03-19 2022-06-02 Cerecor Inc Methods for treating symptomatic orthostatic hypotension
CA3180948A1 (en) * 2020-06-02 2021-12-09 Mohamed Hussein Hamdan Sublingual formulation for hypotension and syncope
TW202345817A (zh) * 2022-03-28 2023-12-01 美商施萬生物製藥研發 Ip有限責任公司 治療患有多系統萎縮之個體的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104815A (en) 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
ES2395868T3 (es) 2007-03-12 2013-02-15 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de la hipotensión mediada neuralmente
PT2358674E (pt) 2008-11-14 2013-03-05 Theravance Inc Processo de preparação de compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
CN104220059A (zh) 2012-01-31 2014-12-17 灵北Na有限公司 通过给予屈昔多巴来改善姿势稳定性
WO2014174425A2 (en) * 2013-04-24 2014-10-30 Mahesh Kandula Compositions and methods for the treatment of orthostasis and neurological diseases
MX2016000219A (es) * 2013-07-08 2016-05-31 Auspex Pharmaceuticals Inc Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.

Also Published As

Publication number Publication date
CL2019000377A1 (es) 2019-05-31
BR112019003201A2 (pt) 2019-10-01
JP2020023552A (ja) 2020-02-13
SG11201901477PA (en) 2019-03-28
CN109640989A (zh) 2019-04-16
MY194181A (en) 2022-11-17
IL288194B1 (en) 2023-11-01
TWI731153B (zh) 2021-06-21
AU2017321016B2 (en) 2020-04-23
JP2019528303A (ja) 2019-10-10
US20180055831A1 (en) 2018-03-01
WO2018044667A1 (en) 2018-03-08
IL288194A (en) 2022-01-01
CA3032168C (en) 2020-04-21
CN115813923A (zh) 2023-03-21
CO2019001137A2 (es) 2019-02-19
MX2019001915A (es) 2019-07-15
JP6853345B2 (ja) 2021-03-31
JP2023159438A (ja) 2023-10-31
JP2021167344A (ja) 2021-10-21
US10238642B2 (en) 2019-03-26
ZA201900640B (en) 2019-10-30
NZ750392A (en) 2020-08-28
EP3506900A1 (en) 2019-07-10
PH12019500252A1 (en) 2019-06-03
IL288194B2 (en) 2024-03-01
KR20190040341A (ko) 2019-04-17
RU2723095C1 (ru) 2020-06-08
CA3032168A1 (en) 2018-03-08
AU2017321016A1 (en) 2019-02-21
CN115770244A (zh) 2023-03-10
KR102054208B1 (ko) 2019-12-10
TW201811329A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
PH12019500252A1 (en) Compound for use in the treatment of neurogenic orthostatic hypotension
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
MX2018010191A (es) Inhibidores de glucosidasa.
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
EA201691421A1 (ru) Гетероарилы и их применение
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201590330A1 (ru) Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения
AR103680A1 (es) Inhibidores selectivos de bace1
EA201692480A1 (ru) Фармацевтическая композиция
EA201692470A1 (ru) Фармацевтические комбинации
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201892235A1 (ru) Гранулированная композиция для перорального применения
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
AR107163A1 (es) Inhibidores de quinasa
BR112016025244A2 (pt) uso de ácido 1,3-propanodissulfônico ou sais farmaceuticamente aceitáveis dos mesmos para o tratamento de sarcoidose.
MX2017008893A (es) Peptidos antagonistas de prgc.
AR101109A1 (es) Forma polimórfica del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina

Legal Events

Date Code Title Description
FG Grant or registration